Transcript Scarica il programma

10
Nadia Galizzi | Milano
LONG-TERM EFFICACY AND SAFETY OF RILPIVIRINE
PLUS ABACAVIR AND LAMIVUDINE IN HIV-1 INFECTED
PATIENTS WITH UNDETECTABLE VIRAL LOAD
(TMC278HTX4002 STUDY)
HIV
FINAL CONTEST | ROMA 29/30 SETTEMBRE 2016 | WORLDHOTEL RIPA
GIOVEDÌ 29 SETTEMBRE 2016
11
Susanna Giache’ | Firenze
EPATITE B NELLE GRAVIDE MIGRANTI E I LORO
CONVIVENTI: STUDIO EPIDEMIOLOGICO NEL
SETTING DI ROMA
Epatiti
12
Chiara Montrucchio | Torino
ALGORITMO DIAGNOSTICO-ASSISTENZIALE
PER LA PREVENZIONE PRIMARIA DI MALATTIA
CARDIOVASCOLARE E METABOLICA NEL PAZIENTE HIV
POSITIVO: STUDIO PROSPETTICO SU FATTORI DI
RISCHIO E MARKERS DI DANNO PRECOCE
HIV
13
Ilaria Motta | Torino
INDIVIDUALIZATION OF ANTITUBERCULAR TREATMENT: Miscellanea
EVALUATION OF PHARMACOLOGICAL DETERMINANTS OF
TREATMENT RESPONSE
Ore 10.30
Ore 11.00
Ore 11.30
Ore 13.00
Ore 14.00
Ore 16.30
Ore 16.45
Ore 18.45
Ore 20.15
14
Stefano Nicole’ | Verona
DOLUTEGRAVIR MONTHERAPY IN HIV-INFECTED NAIVE HIV
PATIENTS WITH <100.000 COPIES/ML HIV RNA LOAD,
AN UPDATE OF A LITTLE COHORT IN VERONA
VENERDÌ 30 SETTEMBRE 2016
15
Silvio Ragozzino | Salamanca (Spagna) MICRORNAS EXPRESSION IN PATIENTS WITH
CANDIDEMIA
Miscellanea
16
Alessandra Ricciardi | Roma
PNEUMOCYSTIS JIROVECII PNEUMONIA (PCP) AT
MAJOR RISK OF DEATH IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE: A RETROSPECTIVE ANALYSIS
ON 116 CASES
Miscellanea
17
Nicoletta Riva | Reggio Emilia
FRAILTY PROGRESSION IN STAGES OF REPRODUCTIVE
AGING: A PROSPECTIVE STUDY IN HIV INFECTED
WOMEN ENTERING MENOPAUSE
HIV
18
Roberto Rossotti | Milano
SICUREZZA ELETTROCARDIOLOGICA DI REGIMI AD
Epatiti
AZIONE DIRETTA ANTI-HCV BASATI SU SOFOSBUVIR IN
UNA COORTE DI SOGGETTI HIV/HCV CO-INFETTI
19
Elisabetta Teti | Roma
HCV CARE CASCADE AMONG INJECTION DRUG USERS: Epatiti
MEET, TEST AND TREAT WITH COMPLIANCE A HARD TO
REACH VULNERABLE POPULATION
20
Giacomo Vandi | Bologna
ABDOMINAL TUBERCULOSIS IN A LOW-INCIDENCE
COUNTRY: A SINGLE CENTRE EXPERIENCE ON 13
PATIENTS INVSTIGATED WITH 18F-FDG PET/CT
Ore 9.00
Ore 11.00
Ore 11.15
Ore 13.15
Ore 14.15
Ore 16.00
Ore 16.30
Registrazione dei partecipanti
Saluti di apertura
Presentazione e discussione dei contributi scientifici
Lunch
Presentazione e discussione dei contributi scientifici
Coffee break
Presentazione e discussione dei contributi scientifici
Chiusura dei lavori
Ritrovo per la cena
STEERING COMMITTE
MASSIMO ANDREONI, ROMA | GIOACCHINO ANGARANO, BARI | MASSIMO GALLI, MILANO |
ADRIANO LAZZARIN, MILANO | CRISTINA MUSSINI, MODENA | CLAUDIO VISCOLI, GENOVA |
VINCENZO VULLO, ROMA
under 40 | INFECTION LAB
2016
GIOVANI INFETTIVOLOGI A CONFRONTO
TALENT SCOUT TEAM
GIUSEPPE BRUNO, BARI | SEFORA CASTELLETTI, ANCONA | ERICA FRANCESCHINI, MODENA |
ANDREA GIACOMELLI, MILANO | GAETANO MAFFONGELLI, ROMA | FULVIA MAZZAFERRI, VERONA |
JESSICA MENCARINI, FIRENZE | LAURA NICOLINI, GENOVA | ALESSANDRA OLIVA, ROMA |
MARCO RIPA, MILANO | SARA TEDESCHI, BOLOGNA | MARCELLO TRIZZINO, PALERMO
C O N I L C O N T R I B U T O I N C O N D I Z I O N AT O D I
Comunicazioni orali
Coffee break
Comunicazioni orali
Lunch
Presentazione dei lavori finalisti
Cerimonia di premiazione
Chiusura dei lavori
FINAL CONTEST > ROMA 29/30 SETTEMBRE 2016 | WORLDHOTEL RIPA
Miscellanea
WORLDHOTEL RIPA: Via degli Orti di Trastevere, 3 - 00153 Roma
M AT T I O L I 1 8 8 5 . C O M
INFECTIONLAB.IT
COMUNICAZIONI ORALI | GIOVEDÌ 29 SETTEMBRE 2016 ORE 11.30
1
Marco Iannetta | Roma
NATALIZUMAB AFFECTS T-CELL PHENOTYPE IN MULTI- Miscellanea
PLE SCLEROSIS: IMPLICATIONS FOR JCV REACTIVATION
2
Giorgio Bozzi | Milano
NO EVIDENCE OF ONGOING REPLICATION IN
TISSUE COMPARTMENTS DURING COMBINATION
ANTIRETROVIRAL THERAPY
HIV
EMERGING GENOTYPE E OF HEPATITIS B VIRUS IN
YOUNG AFRICAN MIGRANTS IN ROME: NEW CLINICAL
AND VIROLOGICAL SETTINGS
Epatiti
HIV
3
Vincenzo Malagnino | Roma
Filippo Del Puente | Genova
BONE STATUS EVALUATION BY QUS IN PATIENTS
PERINATALLY INFECTED WITH HIV-1. A LONGITUDINAL
STUDY FROM CHILDHOOD TO EARLY ADULT AGE
5
Francesca Rinaldi | Pavia
MEDICAL TREATMENT VERSUS “WATCH AND WAIT” IN Miscellanea
THE CLINICAL MANAGEMENT OF CE3B ECHINOCOCCAL
CYSTS OF THE LIVER
6
Maria Mazzitelli | Catanzaro
STUDIO CARDIAC: (CARDIAC DISEASES IN ANTIVIRAL
Epatiti
THERAPY FOR HCV). VALUTAZIONE DELLA FUNZIONALITÀ
CARDIACA IN PAZIENTI CON INFEZIONE DA HCV IN
TRATTAMENTO CON NUOVI DAA
8
9
10
11
12
13
Filippo Turrini | Milano
Giuseppina Musumeci | Bologna
Filippo Lagi | Firenze
Giovanni Satta | Londra
Nicolò Girometti | Bologna
Emmanuele Venanzi-Rullo | Messina
Esther Merlini | Milano
Alessio Strazzulla | Catanzaro
IS NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN
USEFUL IN HEPATITIS C VIRUS INFECTION?
Epatiti
15
Francesco Di Gennaro | Bari
THE SOUND OF TB: ROLE OF LUNG ULTRASOUND IN
THE DIAGNOSIS AND FOLLOW-UP OF PULMONARY
TUBERCULOSIS IN RESOURCE LIMITED SETTINGS
Miscellanea
16
Michele Bartoletti | Bologna
BLOODSTREAM INFECTION IN CIRRHOTIC PATIENTS:
A PROSPECTIVE MULTICENTER STUDY (BICHROME)
Antibiotici e
antifungini
17
Margherita Macera | Napoli
CB2-63 POLYMORPHISM AND IMMUNE-MEDIATED
DISEASES ASSOCIATED WITH HCV CHRONIC INFECTION
Epatiti
HIGHER LEVELS OF OSTEOPROTEGERIN AND IMMUNE
ACTIVATION/IMMUNOSENESCENCE MARKERS ARE
CORRELATED WITH CONCOMITANT BONE AND
ENDOVASCULAR DAMAGE IN HIV-SUPPRESSED
PATIENTS
HIV
18
4
7
14
THE HIV-1 TRANSCRIPTIONAL REPRESSOR TRIM22 IS
A NOVEL DETERMINANT OF PROVIRAL LATENCY AND
DISEASE PROGRESSION
HIV
M48U1 AND TENOFOVIR COMBINATION
SYNERGISTICALLY INHIBITS HIV-1 INFECTION IN
ACTIVATED PBMCS AND HUMAN CERVICOVAGINAL
HISTOCULTURES
HIV
PROPOSAL FOR A NEW SCORE-BASED APPROACH TO
IMPROVE EFFICIENCY OF DIAGNOSTIC LABORATORY
WORKFLOW FOR ACUTE BACTERIAL MENINGITIS IN
ADULTS
Antibiotici e
antifungini
GENETIC VARIATION IN MYCOBACTERIUM
Miscellanea
TUBERCULOSIS ISOLATES FROM A LONDON OUTBREAK
ASSOCIATED WITH ISONIAZID RESISTANCE
OUTCOMES OF ACUTELY HIV-1 INFECTED
INDIVIDUALS FOLLOWING RAPID ANTIRETROVIRAL
THERAPY INITIATION
HIV
AMFOTERICINA IN AEROSOL PER IL TRATTAMENTO
DELL’ASPERGILLOSI POLMONARE INVASIVA, UNO
STUDIO DI COORTE RETROSPETTIVO OSSERVAZIONALE
Antibiotici e
antifungini
ASSOCIATION BETWEEN MUCOSAL-ASSOCIATED
INVARIANT T (MAIT) CELLS AND GUT MICROBIOME:
FRIEND OR FOE IN CHRONIC VIRAL INFECTIONS?
HIV
Alessandra D’Abramo | Roma
19
Silvia Corcione | Torino
ANTIMICROBIAL STEWARDSHIP IN A LONG TERM
ACUTE CARE HOSPITAL USING OFFSITE ELECTRONIC
MEDICAL RECORD AUDIT
Antibiotici e
antifungini
20
Paola Ronzi | Milano
ATTIVITÀ E TOSSICITÀ IN VITRO DEI COMPOSTI
PEPTIDOMIMETICI BICICLICI COME INIBITORI DELLA
PROTEASI DI HIV-1
HIV
21
Alessandra Ruggiero | Liverpool (UK)
DURING STABLY SUPPRESSIVE ANTIRETROVIRAL
HIV
THERAPY INTEGRATED HIV-1 DNA LOAD IN PERIPHERAL
BLOOD IS ASSOCIATED WITH THE FREQUENCY OF
CD8 CELLS EXPRESSING HLA-DR/DP/DQ
22
Valentina Di Cristo | Milano
FACTORS INVOLVED IN CONTINUANCE OF
ATAZANAVIR-BASED REGIMENS : RESULTS FROM
A COHORT OF HIV1-POSITIVE PATIENTS
HIV
23
Sara Mazzanti | Ancona
EPIDEMIOLOGIA, CARATTERISTICHE CLINICHE E
MORTALITÀ DELLA CANDIDEMIA NELL’ETÀ AVANZATA
Antibiotici e
antifungini
24
Marianna Menozzi | Modena
CD4/CD8 RATIO MATTERS TO AGE RELATED HEALTH
OUTCOMES IN HIV INFECTED PATIENTS WITH
COMORBIDITIES, FRAILTY AND DISABILITY
HIV
COMUNICAZIONI ORALI | VENERDÌ 30 SETTEMBRE 2016 ORE 9.00
25
Alberto Antonelli | Firenze
FIRST DETECTION OF A MULTIRESISTANCE
TRANSPOSON OF ORIGINAL STRUCTURE HARBOURING
CFR GENE AND A NOVEL PUTATIVE EFFLUX PUMP IN A
LINEZOLID-RESISTANT MRSA
Antibiotici e
antifungini
26
Alessia Bertoldi | Bologna
LONGITUDINAL EVALUATION OF RESERVOIR SIZE DECAY HIV
IN NAÏVE HIV PATIENTS STARTING ART
27
Annalisa De Rosa | Roma
EXTENSIVELY DRUG RESISTANT PSEUDOMONAS
Antibiotici e
AERUGINOSA: A STUDY ON CARBAPENEM RESISTANCE antifungini
MECHANISMS
28
Renato Pascale | Bologna
TIGECYCLINE, AN ECOLOGICAL CHOICE?
RETROSPECTIVE COHORT STUDY OF COLONIZATION
OR INFECTION RISK WITH CARBAPENEMS-RESISTANT
KLEBSIELLA PNEUMONIAE OR CLOSTRIDIUM DIFFICILE
FOLLOWING ANTIBIOTIC TREATMENT OF INTRAABDOMINAL INFECTION
Antibiotici e
antifungini
29
Francesca Bai | Milano
FACTORS ASSOCIATED WITH ANAL/CERVICAL HPV
INFECTION AND DYSPLASIA IN A COHORT OF
HIV-INFECTED MALE AND FEMALE PATIENTS
HIV
30
Sara Veloci | Firenze
HBV IN GRAVIDANZA: ANALISI DI UNA POPOLAZIONE
DI 213 GESTANTI E VALUTAZIONE DELL’OUTCOME
DEI NATI DA DONNE CON ELEVATA VIREMIA PRESSO
L’AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI,
FIRENZE
Epatiti
31
Emanuele Foca’ | Brescia
LIVER FIBROSIS PROGRESSION AND CLINICAL
HIV
OUTCOMES ARE INTERTWINED: ROLE OF CD4+ T-CELL
COUNT AND NRTI EXPOSURE FROM A LARGE COHORT
OF HIV/HCV CO-INFECTED PATIENTS WITH DETECTABLE
HCV RNA. A MASTER COHORT STUDY
32
Stefania De Pascalis | Napoli
ITPASE ACTIVITY MODULATES THE SEVERITY OF
ANEMIA IN PATIENTS WITH HCV-RELATED CIRRHOSIS
TREATED WITH RIBAVIRIN-CONTAINING IFN-FREE
REGIMENS
39
Lorenzo Zammarchi | Firenze
A SCOPING REVIEW OF COST-EFFECTIVENESS
OF SCREENING AND TREATMENT FOR LATENT
TUBERCOLOSIS INFECTION IN MIGRANTS FROM
HIGH-INCIDENCE COUNTRIES
Miscellanea
40
Valeria Cento | Roma
HIGH EFFICACY OF HCV RESISTANCE-GUIDED
RETREATMENT STRATEGIES AFTER PROTEASE
INHIBITORS FAILURE IN REAL-LIFE SETTINGS
Epatiti
SESSIONE POSTER | I contributi scientifici dovranno essere esposti negli spazi previsti
entro l’inizio dei lavori di giovedì 29 settembre
1
Irene Adami | Verona
EFFICACIA DELLE NUOVE TERAPIE CON DAAS IN
PAZIENTI CON INFEZIONE DA HIV AFFETTI DA EPATITE
CRONICA HCV-CORRELATA
Epatiti
2
Loredana Alessio | Napoli
PREVALENZA DI INFEZIONE DA VIRUS DELL’EPATITE
B, DA VIRUS DELL’EPATITE C E DA VIRUS
DELL’IMMUNODEFICIENZA UMANA IN UNA
POPOLAZIONE IMMIGRATA RESIDENTE IN CAMPANIA:
CARATTERISTICHE DEMOGRAFICHE, CLINICHE E
VIROLOGICHE
Epatiti
3
Andrea Andolina | Milano
CLINICAL AND VIROLOGICAL CHARACTERISTICS OF
HIV NEG. AND HIV POS. INDIVIDUALS INFECTED BY
HCV GENOTYPE 4: DATA FROM AN ITALIAN CENTER
Epatiti
4
Elisa Biliotti | Roma
EFFECT OF INTERFERON FREE ANTIVIRAL TREATMENT ON Epatiti
LIPID METABOLISM, LIPID OXIDATION AND
INSULINRESISTANCE IN CHRONIC HEPATITIS C PATIENTS
WITH ADVANCED LIVER DISEASE
5
Andrea Brasacchio | Modena
ANTIMICROBIAL STEWARDSHIP IN A
Antibiotici e
GASTROENTEROLOGY DEPARTMENT: ONE YEAR
antifungini
EXPERIENCE AT THE UNIVERSITY HOSPITAL OF MODENA
Epatiti
33
Valentina Svicher | Roma
IDENTIFICATION AND CHARACTERIZATION OF SPECIFIC Epatiti
GENETIC ELEMENTS IN HBV SURFACE GLYCOPROTEIN
CORRELATED WITH HEPATOCELLULAR CARCINOMA: AN
IN VIVO AND IN VITRO ANALYSIS
34
Stefania E. Cannizzo | Milano
ROLE OF MICROBIAL TRANSLOCATION IN HIV INFECTED HIV
PATIENTS DURING SUPPRESSIVE ANTIRETROVIRAL
THERAPY (CART) AND CAUSAL RELATIONSHIP WITH
HIV-DRIVEN BONE IMPAIRMENT
35
Lorenzo Onorato | Napoli
OCCULT HBV INFECTION IN HCC AND CIRRHOTIC
Epatiti
TISSUE OF HBSAG-NEGATIVE PATIENTS: A VIROLOGICAL
AND CLINICAL STUDY
6
Lucia Brescini | Ancona
TRIPANOSOMIASI AFRICANA DA T. BRUCEI
Miscellanea
RHODESIENSE: DESCRIZIONE DI UN CASO E REVISIONE
DELLA LETTERATURA
36
Francesco Saladini | Siena
PRELIMINARY EVALUATION OF ANTIVIRAL ACTIVITY OF HIV
CANDIDATE HIV INHIBITORS TARGETING HUMAN DDX3
PROTEIN
7
Maddalena Cordioli | Verona
37
Lucio Boglione | Torino
TREATMENT WITH DACLATASVIR AND SOFOSBUVIR FOR Epatiti
24 WEEKS WITHOUT RIBAVIRIN IN CIRRHOTIC PATIENTS
WHO FAILED FIRST-GENERATION PROTEASE INHIBITORS
STUDIO PILOTA DI VALIDAZIONE DI TEST RAPIDI PER
HIV
HIV E SIFILIDE ED IDENTIFICAZIONE DI PREDITTORI
CLINICI E COMPORTAMENTALI RISPETTO ALL’ACCESSO
AL TESTING IN UN GRUPPO DI MSM
8
Giovanni Di Caprio | Napoli
38
Daniele Roberto Giacobbe | Genova
LOWER SENSITIVITY OF SERUM (1,3)-BETA-D-GLUCAN Antibiotici e
FOR THE DIAGNOSIS OF CANDIDEMIA DUE TO CANDIDA antifungini
PARAPSILOSIS
TM6SF2 E167E VARIANT IS ASSOCIATED WITH A HIGHER HIV
SERUM CHOLESTEROL VALUES AND CAROTID INTIMAMEDIA THICKNESS IN PATIENTS WITH HIV INFECTION
9
Iacopo Franconi | Modena
FRAILTY IMPROVES IN BOTH YOUNG AND OLD HIV PATIENTS UNDERGOING ATAZANAVIR BASED REGIMENS
HIV